<p>吉利德科学（NASDAQ:GILD - 获取免费报告）在周二发布的一份报告中，股票分析师将其目标价格从 161.00 美元下调至 150.00 美元，MarketScreener 报道。该公司目前对这家生物制药公司的股票给予 “跑赢大盘” 的评级。大和证券集团的目标价格表明，股票当前价格有 14.66% 的上涨潜力。</p>
<p>获取 <strong>吉利德科学</strong> 的提醒：</p>
<ul>
<li>3 只适合轮动市场的蓝筹股</li>
</ul>
<p>其他几家研究公司也最近对 GILD 发表了评论。巴克莱在 2 月 20 日的报告中开始覆盖吉利德科学的股票。他们给予 “等权重” 评级，并设定 155.00 美元的目标价格。富国银行在 2 月 11 日的报告中将吉利德科学的目标价格从 150.00 美元上调至 165.00 美元，并给予该股票 “超配” 评级。TD Cowen 在 2 月 11 日的研究报告中将吉利德科学的目标价格从 145.00 美元上调至 160.00 美元，并给予该股票 “买入” 评级。Cantor Fitzgerald 在 4 月 10 日的研究报告中将吉利德科学的目标价格从 155.00 美元下调至 115.00 美元，并对该股票设定 “超配” 评级。最后，瑞穗在 2 月 18 日的研究报告中将吉利德科学的目标价格从 140.00 美元上调至 170.00 美元，并给予该公司 “跑赢大盘” 评级。24 位投资分析师对该股票给予 “买入” 评级，4 位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价格为 156.62 美元。</p>
<p><strong>查看我们关于 GILD 的最新股票报告</strong></p>
<h2>吉利德科学股票表现</h2>
<ul>
<li>这 3 只现金流机器在不确定的市场中提供稳定性</li>
</ul>
<p>在周二的交易中，GILD 上涨 1.15 美元，达到 130.82 美元。该公司交易了 392,453 股，与其平均交易量 6,687,137 股相比有所减少。该公司的市值为 1624.2 亿美元，市盈率为 17.85，贝塔值为 0.31。公司快速比率为 1.77，流动比率为 1.97，债务与股本比率为 0.89。吉利德科学的年内最低价为 104.46 美元，年内最高价为 157.29 美元。该股票的 50 日移动平均线为 137.46 美元，200 日移动平均线为 133.40 美元。</p>
<p>吉利德科学（NASDAQ:GILD - 获取免费报告）最后一次发布财报是在 5 月 7 日，生物制药公司报告本季度每股收益为 2.03 美元，超出分析师共识预期的 1.91 美元，超出 0.12 美元。该公司本季度的收入为 69.6 亿美元，而共识预期为 69.1 亿美元。吉利德科学的净利润率为 30.99%，股本回报率为 48.19%。与去年同期相比，该公司的收入增长了 4.4%。在去年同期，该公司每股收益为 1.81 美元。吉利德科学已将其 2026 财年的指导目标设定为-1.050 至-0.650 每股收益。作为一个整体，股票分析师预测吉利德科学在当前财年将发布-0.78 每股收益。</p>
<h2>内部人士下注</h2>
<ul>
<li>3 只现金流机器，投资者可能希望在 2026 年之前拥有</li>
</ul>
<p>在相关消息中，首席财务官 Andrew D. Dickinson 在 5 月 15 日的交易中出售了 3,000 股该股票。股票以 132.27 美元的平均价格出售，总交易额为 396,810.00 美元。交易后，首席财务官持有 173,191 股公司股票，价值约 22,907,973.57 美元。这笔交易代表其持股比例下降了 1.70%。该交易在向证券交易委员会提交的文件中披露，可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席执行官 Daniel Patrick O'day 在 4 月 28 日的交易中出售了 10,000 股公司的股票。该股票以 129.16 美元的平均价格出售，总交易额为 1,291,600.00 美元。交易完成后，首席执行官直接持有 632,567 股公司的股票，价值 81,702,353.72 美元。这代表其持股比例下降了 1.56%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在上个季度共出售了 63,000 股公司股票，价值 8,523,570 美元。0.30% 的股票由公司内部人士持有。</p>
<h2>机构投资者对吉利德科学的看法</h2>
<p>一些对冲基金和其他机构投资者最近修改了他们对 GILD 的持股。先锋集团在第四季度增持了吉利德科学的股份，增幅为 1.8%。先锋集团目前拥有 121,097,336 股生物制药公司的股票，价值 14,863,487,000 美元，在上个季度又购买了 2,113,692 股。道富银行在第四季度增持了吉利德科学的股份，增幅为 1.9%。道富银行目前拥有 60,240,518 股生物制药公司的股票，价值 7,393,921,000 美元，在此期间又购买了 1,151,213 股。T. Rowe Price Associates Inc. MD 在第四季度增持了吉利德科学的股份，增幅为 4.5%。T. Rowe Price Associates Inc. MD 目前拥有 27,698,660 股生物制药公司的股票，价值 3,399,734,000 美元，在上个季度又收购了 1,195,269 股。美国银行在第四季度增持了吉利德科学的股份，增幅为 15.2%。美国银行目前拥有 23,121,620 股生物制药公司的股票，价值 2,837,948,000 美元，在此期间又收购了 3,046,688 股。最后，挪威银行在第四季度购买了吉利德科学的新股份，价值约 2,617,152,000 美元。机构投资者持有该公司 83.67% 的股票。</p>
<h2>关于吉利德科学</h2>
<p>(获取免费报告)</p>
<p>吉利德科学公司成立于 1987 年，总部位于加利福尼亚州福斯特城，是一家生物制药公司，专注于在高未满足医疗需求领域的药物发现、开发和商业化。该公司最初在抗病毒疗法方面建立了声誉，随后扩展到肿瘤学、细胞治疗和炎症疾病。吉利德在全球范围内运营研究和商业组织，进行临床开发并在全球市场销售药物。</p>
<p>吉利德的产品组合以针对 HIV 和病毒性肝炎的抗病毒疗法为基础。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比吉利德科学更好的股票</li>
<li>重塑人工智能：NextEra Energy 引发巨型合并</li>
<li>切换开关：福特会是下一个大能源股票吗？</li>
<li>纳米核能的新交易是否提升了前景？</li>
<li>2026 年内部人士购买的三只分红股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在吉利德科学吗？</h2>
<p>在你考虑吉利德科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而吉利德科学并不在名单上。</p>
<p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

吉利德科学

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

<p>大和证券集团已将吉利德科学（NASDAQ:GILD）的目标价格从 161.00 美元下调至 150.00 美元，同时维持 “跑赢大盘” 的评级。这个新目标暗示着 14.66% 的潜在上涨空间。其他分析师的看法各不相同，巴克莱设定了 155.00 美元的目标，而富国银行则将其目标上调至 165.00 美元。吉利德的股票目前交易价格为 130.82 美元，市值为 1624.2 亿美元，市盈率为 17.85</p>

<p>Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price objective dropped by stock analysts at Daiwa Securities Group from $161.00 to $150.00 in a report released on Tuesday,MarketScreener reports. The firm presently has an &#34;outperform&#34; rating on the biopharmaceutical company's stock. Daiwa Securities Group's target price indicates a potential upside of 14.66% from the stock's current price.</p>
<div class="lb-trans"><p>吉利德科学（NASDAQ:GILD - 获取免费报告）在周二发布的一份报告中，股票分析师将其目标价格从 161.00 美元下调至 150.00 美元，MarketScreener 报道。该公司目前对这家生物制药公司的股票给予 “跑赢大盘” 的评级。大和证券集团的目标价格表明，股票当前价格有 14.66% 的上涨潜力。</p>
</div><p>Get <strong>Gilead Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>吉利德科学</strong> 的提醒：</p>
</div><ul>
<li>3 Blue-Chip Stocks Built for a Rotating Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只适合轮动市场的蓝筹股</li>
</ul>
</div><p>Several other research firms also recently commented on GILD. Barclays began coverage on shares of Gilead Sciences in a report on Friday, February 20th. They issued an &#34;equal weight&#34; rating and a $155.00 price objective for the company. Wells Fargo &amp; Company increased their price objective on Gilead Sciences from $150.00 to $165.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, February 11th. TD Cowen raised their target price on Gilead Sciences from $145.00 to $160.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, February 11th. Cantor Fitzgerald decreased their price target on Gilead Sciences from $155.00 to $115.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday, April 10th. Finally, Mizuho raised their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an &#34;outperform&#34; rating in a research report on Wednesday, February 18th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $156.62.</p>
<div class="lb-trans"><p>其他几家研究公司也最近对 GILD 发表了评论。巴克莱在 2 月 20 日的报告中开始覆盖吉利德科学的股票。他们给予 “等权重” 评级，并设定 155.00 美元的目标价格。富国银行在 2 月 11 日的报告中将吉利德科学的目标价格从 150.00 美元上调至 165.00 美元，并给予该股票 “超配” 评级。TD Cowen 在 2 月 11 日的研究报告中将吉利德科学的目标价格从 145.00 美元上调至 160.00 美元，并给予该股票 “买入” 评级。Cantor Fitzgerald 在 4 月 10 日的研究报告中将吉利德科学的目标价格从 155.00 美元下调至 115.00 美元，并对该股票设定 “超配” 评级。最后，瑞穗在 2 月 18 日的研究报告中将吉利德科学的目标价格从 140.00 美元上调至 170.00 美元，并给予该公司 “跑赢大盘” 评级。24 位投资分析师对该股票给予 “买入” 评级，4 位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价格为 156.62 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on GILD</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 GILD 的最新股票报告</strong></p>
</div><h2>Gilead Sciences Stock Performance</h2>
<div class="lb-trans"><h2>吉利德科学股票表现</h2>
</div><ul>
<li>These 3 Cash Flow Machines Provide Stability in Uncertain Markets</li>
</ul>
<div class="lb-trans"><ul>
<li>这 3 只现金流机器在不确定的市场中提供稳定性</li>
</ul>
</div><p>GILD traded up $1.15 during trading on Tuesday, hitting $130.82. 392,453 shares of the company traded hands, compared to its average volume of 6,687,137. The firm has a market cap of $162.42 billion, a P/E ratio of 17.85 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences has a one year low of $104.46 and a one year high of $157.29. The stock's fifty day moving average is $137.46 and its 200 day moving average is $133.40.</p>
<div class="lb-trans"><p>在周二的交易中，GILD 上涨 1.15 美元，达到 130.82 美元。该公司交易了 392,453 股，与其平均交易量 6,687,137 股相比有所减少。该公司的市值为 1624.2 亿美元，市盈率为 17.85，贝塔值为 0.31。公司快速比率为 1.77，流动比率为 1.97，债务与股本比率为 0.89。吉利德科学的年内最低价为 104.46 美元，年内最高价为 157.29 美元。该股票的 50 日移动平均线为 137.46 美元，200 日移动平均线为 133.40 美元。</p>
</div><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company's revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. As a group, equities analysts predict that Gilead Sciences will post -0.78 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>吉利德科学（NASDAQ:GILD - 获取免费报告）最后一次发布财报是在 5 月 7 日，生物制药公司报告本季度每股收益为 2.03 美元，超出分析师共识预期的 1.91 美元，超出 0.12 美元。该公司本季度的收入为 69.6 亿美元，而共识预期为 69.1 亿美元。吉利德科学的净利润率为 30.99%，股本回报率为 48.19%。与去年同期相比，该公司的收入增长了 4.4%。在去年同期，该公司每股收益为 1.81 美元。吉利德科学已将其 2026 财年的指导目标设定为-1.050 至-0.650 每股收益。作为一个整体，股票分析师预测吉利德科学在当前财年将发布-0.78 每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>3 Cash-Flow Machines Investors May Want Heading Into 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只现金流机器，投资者可能希望在 2026 年之前拥有</li>
</ul>
</div><p>In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares of the company's stock, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares of the company's stock, valued at $81,702,353.72. This represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 63,000 shares of company stock valued at $8,523,570 over the last quarter. 0.30% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Andrew D. Dickinson 在 5 月 15 日的交易中出售了 3,000 股该股票。股票以 132.27 美元的平均价格出售，总交易额为 396,810.00 美元。交易后，首席财务官持有 173,191 股公司股票，价值约 22,907,973.57 美元。这笔交易代表其持股比例下降了 1.70%。该交易在向证券交易委员会提交的文件中披露，可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席执行官 Daniel Patrick O'day 在 4 月 28 日的交易中出售了 10,000 股公司的股票。该股票以 129.16 美元的平均价格出售，总交易额为 1,291,600.00 美元。交易完成后，首席执行官直接持有 632,567 股公司的股票，价值 81,702,353.72 美元。这代表其持股比例下降了 1.56%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在上个季度共出售了 63,000 股公司股票，价值 8,523,570 美元。0.30% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Gilead Sciences</h2>
<div class="lb-trans"><h2>机构投资者对吉利德科学的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. State Street Corp boosted its position in Gilead Sciences by 1.9% during the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock valued at $7,393,921,000 after buying an additional 1,151,213 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company's stock worth $3,399,734,000 after acquiring an additional 1,195,269 shares during the last quarter. Bank of America Corp DE increased its position in shares of Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares during the period. Finally, Norges Bank bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $2,617,152,000. Institutional investors own 83.67% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近修改了他们对 GILD 的持股。先锋集团在第四季度增持了吉利德科学的股份，增幅为 1.8%。先锋集团目前拥有 121,097,336 股生物制药公司的股票，价值 14,863,487,000 美元，在上个季度又购买了 2,113,692 股。道富银行在第四季度增持了吉利德科学的股份，增幅为 1.9%。道富银行目前拥有 60,240,518 股生物制药公司的股票，价值 7,393,921,000 美元，在此期间又购买了 1,151,213 股。T. Rowe Price Associates Inc. MD 在第四季度增持了吉利德科学的股份，增幅为 4.5%。T. Rowe Price Associates Inc. MD 目前拥有 27,698,660 股生物制药公司的股票，价值 3,399,734,000 美元，在上个季度又收购了 1,195,269 股。美国银行在第四季度增持了吉利德科学的股份，增幅为 15.2%。美国银行目前拥有 23,121,620 股生物制药公司的股票，价值 2,837,948,000 美元，在此期间又收购了 3,046,688 股。最后，挪威银行在第四季度购买了吉利德科学的新股份，价值约 2,617,152,000 美元。机构投资者持有该公司 83.67% 的股票。</p>
</div><h2>About Gilead Sciences</h2>
<div class="lb-trans"><h2>关于吉利德科学</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.</p>
<div class="lb-trans"><p>吉利德科学公司成立于 1987 年，总部位于加利福尼亚州福斯特城，是一家生物制药公司，专注于在高未满足医疗需求领域的药物发现、开发和商业化。该公司最初在抗病毒疗法方面建立了声誉，随后扩展到肿瘤学、细胞治疗和炎症疾病。吉利德在全球范围内运营研究和商业组织，进行临床开发并在全球市场销售药物。</p>
</div><p>Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.</p>
<div class="lb-trans"><p>吉利德的产品组合以针对 HIV 和病毒性肝炎的抗病毒疗法为基础。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Gilead Sciences</li>
<li>Rewiring AI: NextEra Energy Sparks a Mega Merger</li>
<li>Flipping the Switch: Is Ford the Next Big Energy Stock?</li>
<li>Does Nano Nuclear Energy’s New Deal Amp the Outlook?</li>
<li>3 Dividend Stocks With Insiders Buying in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比吉利德科学更好的股票</li>
<li>重塑人工智能：NextEra Energy 引发巨型合并</li>
<li>切换开关：福特会是下一个大能源股票吗？</li>
<li>纳米核能的新交易是否提升了前景？</li>
<li>2026 年内部人士购买的三只分红股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=GILD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gilead Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在吉利德科学吗？</h2>
</div><p>Before you consider Gilead Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑吉利德科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而吉利德科学并不在名单上。</p>
</div><p>While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Market Beat

标普全球医疗股指数 ETF - iShares

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - SPDR

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

Daiwa Securities Group Inc.

巴克莱银行

富国银行

瑞穗金融集团

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Mizuho Financial Group, Inc.

大和证券集团对吉利德科学（NASDAQ:GILD）股票价格发布了悲观的预测